Danaher clears FDA hurdle with Masimo, shares extend rebound on NYSE

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 16:10.

Danaher Corp. (US2358511028) adds a fresh regulatory data point this week. Subsidiary Masimo has received FDA 510(k) clearance for an AI-enabled monitoring feature, while Danaher shares trade on the NYSE with a marked short-term rebound, according to recent market commentary. Simply Wall St analysis on Danaher’s FDA news and valuation

What the FDA clearance changes

The latest FDA 510(k) clearance concerns an AI-enabled feature in Masimo’s Radius VSM wearable that detects opioid-induced respiratory depression in hospital patients, adding to Danaher’s clinical monitoring capabilities. Simply Wall St report on Masimo’s AI feature and FDA approval This follows Danaher’s $9.9 billion acquisition of Masimo, a deal that pushed the group deeper into patient monitoring and added debt to its balance sheet. The Motley Fool discussion of Danaher’s Masimo acquisition and stock reaction

The regulatory green light is notable after earlier investor concerns about Masimo’s patent dispute with Apple over pulse oximetry technology in consumer devices, which had contributed to volatility in both companies’ narratives. The Motley Fool analysis of Apple-related patent issues For Danaher, the clearance reinforces the strategic intent behind the Masimo deal, linking AI-based clinical monitoring with its broader diagnostics portfolio.

How the Danaher chart looks this week

Against this backdrop, Danaher’s NYSE-listed shares show a robust short-term move, with a one-day return of about 5.5% and a 30-day gain close to 9.8% as highlighted by recent equity research. Equity research commentary on Danaher’s recent share performance At a latest close around 188.9 US dollars, the shares sit meaningfully above a recent 20-day low and reflect a recovery move from earlier weakness. Arincen quote overview for Danaher

Despite the rebound, Danaher remains down roughly 22% year-to-date, according to long-form investor analysis that ties the decline to the Masimo acquisition and associated leverage. The Motley Fool review of Danaher’s year-to-date performance The 200-day moving average has acted as a reference line in recent chart commentary, with the current price trading below earlier peaks near 198.6 US dollars seen in the past 50 trading days. MarketBeat price and range data for Danaher

How Danaher makes its money

Danaher generates most of its revenue in life sciences, diagnostics and biotechnology tools, selling instruments, consumables and software to laboratories, pharmaceutical companies and hospitals. Danaher company overview on its core segments Flagship platforms include liquid chromatography and mass spectrometry systems, as well as clinical analyzers and reagents that support drug development and patient testing workflows.

Where the shares trade today

Danaher Corp. shares (US2358511028) most recently traded on the NYSE at around 188.9 US dollars, based on delayed quotes, with a market capitalization near 134 billion US dollars as of the latest close. Arincen snapshot of Danaher’s price and market cap

Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell any security. All data referenced are based on sources considered reliable at the time of writing but may change without notice.